AEThe United Arab Emirates (UAE) has approved the use of Lipfendra, a cholesterol-lowering drug developed by Merck, to address high cholesterol, referred to as a 'silent killer' due to its lack of symptoms but significant risk of heart disease and strokes. The drug was authorized by the US Food and Drug Administration and is now available in the UAE as part of a treatment plan under medical supervision. Clinical trials demonstrated that Lipfendra can reduce LDL cholesterol by up to 59% within 24 weeks. The UAE's Drug Establishment emphasized that the medication should complement a healthy lifestyle, including diet and exercise, and noted that cholesterol levels can be monitored via a simple blood test. Public health authorities encourage annual cholesterol checks and recommend consulting healthcare professionals for personalized treatment plans.
Bias read (Center): The article presents information about a new drug approval without overtly favoring any political ideology. It focuses on health and scientific data, emphasizing the importance of cholesterol management and public health recommendations. While the topic relates to public policy and healthcare, the报道
%2Ffile%2Fdailymaverick%2Fwp-content%2Fuploads%2FDavid-Harrison1-1.jpg&w=3840&q=75&output=webp&we)
